Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients

• Published in: Haematologica (Roma) Vol. 101; no. 11; pp. 1343 - 1350
• Main Authors: Keel, Siobán B., Scott, Angela, Sanchez-Bonilla, Marilyn, Ho, Phoenix A., Gulsuner, Suleyman, Pritchard, Colin C., Abkowitz, Janis L., King, Mary-Claire, Walsh, Tom, Shimamura, Akiko
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.11.2016
• Subjects: Adolescent; Adult; Anemia, Aplastic - genetics; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit - genetics; Family; Female; Genetic Testing; Germ-Line Mutation; Humans; Infant; Male; Mutation; Myelodysplastic Syndromes - genetics; Sequence Analysis, DNA; Young Adult
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2016.149476

The clinical and histopathological distinctions between inherited versus acquired bone marrow failure and myelodysplastic syndromes are challenging. The identification of inherited bone marrow failure/myelodysplastic syndromes is critical to inform appropriate clinical management. To investigate whether a subset of pediatric and young adults undergoing transplant for aplastic anemia or myelodysplastic syndrome have germline mutations in bone marrow failure/myelodysplastic syndrome genes, we performed a targeted genetic screen of samples obtained between 1990-2012 from children and young adults with aplastic anemia or myelodysplastic syndrome transplanted at the Fred Hutchinson Cancer Research Center. Mutations in inherited bone marrow failure/myelodysplastic syndrome genes were found in 5.1% (5/98) of aplastic anemia patients and 13.6% (15/110) of myelodysplastic syndrome patients. While the majority of mutations were constitutional, a RUNX1 mutation present in the peripheral blood at a 51% variant allele fraction was confirmed to be somatically acquired in one myelodysplastic syndrome patient. This highlights the importance of distinguishing germline versus somatic mutations by sequencing DNA from a second tissue or from parents. Pathological mutations were present in DKC1, MPL, and TP53 among the aplastic anemia cohort, and in FANCA, GATA2, MPL, RTEL1, RUNX1, SBDS, TERT, TINF2, and TP53 among the myelodysplastic syndrome cohort. Family history or physical examination failed to reliably predict the presence of germline mutations. This study shows that while any single specific bone marrow failure/myelodysplastic syndrome genetic disorder is rare, screening for these disorders in aggregate identifies a significant subset of patients with inherited bone marrow failure/myelodysplastic syndrome.